



Universiteit  
Leiden

The Netherlands

## **It's about time: novel drug discovery concepts for the molecular pharmacological characterization fo the cannabinoid CB2 receptor**

Bouma, J.

### **Citation**

Bouma, J. (2024, September 11). *It's about time: novel drug discovery concepts for the molecular pharmacological characterization fo the cannabinoid CB2 receptor*. Retrieved from <https://hdl.handle.net/1887/4082998>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4082998>

**Note:** To cite this publication please use the final published version (if applicable).

# List of publications

## Part of this thesis

**Bouma, J.**, Kumar, S.S., van den Berg, B.J.W., van der Horst, C., Hoare, S.R.J., Guba, W., Wittwer, M., Grether, U., van der Stelt, M., Heitman, L.H. (2024). Kinetic multiplex assay to assess biased signaling of clinical agonists at the cannabinoid CB<sub>2</sub> receptor. *Manuscript in preparation*.

**Bouma, J.**, Broekhuis, J.D., van der Horst, C., Kumar, P., Ligresti, A., van der Stelt, M., & Heitman, L.H. (2023). Dual allosteric and orthosteric pharmacology of synthetic analog cannabidiol-dimethylheptyl, but not cannabidiol, on the cannabinoid CB<sub>2</sub> receptor. *Biochemical Pharmacology*, **218**, 115924.

Li, X.\*, Chang, H.\*, **Bouma, J.\***, de Paus, L. V., Mukhopadhyay, P., Palocz, J., Mustafa, M., van der Horst, C., Kumar, S.S., Wu, L., Yu, Y., van den Berg, R.J.B.H.N., Janssen, A.P.A., Lichtman, A., Liu, Z.-J., Pacher, P., van der Stelt, M., Heitman, L.H., Hua, T. (2023). Structural basis of selective cannabinoid CB<sub>2</sub> receptor activation. *Nature Communications*, **14**(1), 1447.

**Bouma, J.**, Soethoudt, M., van Gils, N., Xia, L., van der Stelt, M., & Heitman, L.H. (2022). Cellular assay to study  $\beta$ -arrestin recruitment by the cannabinoid receptors 1 and 2. In *Endocannabinoid Signaling: Methods in Molecular Biology* (pp. 189-199). New York, NY: Springer US.

\* These authors contributed equally

## Other publications

Mach, L., Omran, A., **Bouma, J.**, Radetzki, S., Sykes, D. A., Guba, W., Li, X., Höffelmeyer, C., Hentsch, A., Gazzi, T., Mostinski, Y., Wasinska-Kalwa, M., de Molnier, F., van der Horst, C., von Kries, J.P., Vendrell, M., Hua, T., Veprintsev, D.B., Heitman, L.H., Nazare, M. (2024). Highly Selective Drug-Derived Fluorescent Probes for the Cannabinoid Receptor Type 1 (CB1R). *Manuscript accepted; Journal of Medicinal Chemistry*.

Wasinska-Kalwa, M., Omran, A., Mach, L., **Bouma, J.**, Scipioni, L., Li, X., Radetzki, S., Mostinski, Y., Schippers, M., Gazzi, T., van der Horst, C., Brennecke, B., Hanske, A., Kolomeets, Y., Guba, W., Sykes, D., von Kries, J.P., Broichhagen, J., Hua, T., Veprintsev, D., Heitman, L.H., Oddi, S., Maccarrone, M., Grether, U., Nazare, M. (2024). Visualization of membrane localization and functional state of CB2R pools by matched agonist and inverse agonist probe pairs. *Manuscript submitted*.

Vlachodimou, A., **Bouma, J.**, De Cleyne, M., Berthelot, D., Pype, S., Bosmans, J.P., van Vlijmen, H., Wroblewski, B., Heitman, L.H., IJzerman, A.P. (2023). Kinetic profiling of novel spirobenzo-oxazinepiperidinone derivatives as equilibrative nucleoside transporter 1 inhibitors. *Purinergic Signalling*, 1-13.

## List of publications

Nakladal, D., Buikema, H., Romero, A.R., Lambooy, S.P.H., **Bouma, J.**, Krenning, G., Vogelaar, P., van der Graaf, A.C., Groves, M.R., Kyselovic, J., Henning, R.H., Deelman, L.E. (2019). The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the  $\alpha_1$ -adrenoceptor. *Scientific Reports*, **9**(1), 13.

### Oral and poster communications

- Biased signaling of clinical CB<sub>2</sub>R agonists**
- 2023 **Oncornet2.0 Final symposium** (*poster*)  
Amsterdam, the Netherlands
- 2023 **ACS Fall 2023** (*oral*)  
Hybrid, online presentation
- 2023 **Gordon Research Conference “Cannabinoid Function in the CNS”** (*poster*)  
Barcelona, Spain
- 2023 **Gordon Research Seminar “Cannabinoid Function in the CNS”** (*poster*)  
Barcelona, Spain
- Structural basis of CB<sub>2</sub>R activation**
- 2023 **LACDR Spring symposium** (*poster*)  
Leiden, the Netherlands
- 2023 **Oncode TU/e meeting** (*oral*)  
Leiden, the Netherlands
- 2023 **Guest lecture at F. Hoffmann-La Roche Ltd.** (*oral*)  
Basel, Switzerland
- 2022 **ULLA Summer school** (*poster*)  
Uppsala, Sweden
- 2022 **International Cannabinoid Research Society Meeting** (*oral*)  
Galway, Ireland  
*Awarded predoctoral presentation award*
- 2022 **FIGON Dutch Medicines Day & EufEPS Annual meeting** (*oral*)  
Leiden, the Netherlands  
*Awarded EufEPS WIPS Women in Pharmaceutical Sciences Award 2022*
- Allosteric modulation of CB<sub>2</sub>R**
- 2022 **LACDR Spring symposium** (*poster*)  
Leiden, the Netherlands
- 2021 **FIGON Dutch Medicines Day** (*poster*)  
Leiden, the Netherlands
- 2021 **LACDR Spring symposium** (*poster*)  
Online
- 2020 **LACDR Spring symposium** (*poster*)  
Online

# Curriculum vitae

Jara Bouma was born in Woerden, the Netherlands, on April 4<sup>th</sup> 1996. She graduated from pre-university education at Stellingwerf College, Oosterwolde (Friesland, the Netherlands) in 2014, after which she continued with the Bachelor's program Life Science & Technology at the University of Groningen (Groningen, the Netherlands) with a major in Medical Pharmaceutical Sciences. Her Bachelor internship into the molecular mechanisms of a novel  $\alpha_1$ -adrenoceptor antagonist under supervision of dr. Dalibor Nakladal, dr. Leo Deelman and dr. Hendrik Buikema at the Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (Groningen, the Netherlands), resulted in a co-authorship on a publication. During these three years, she also took the opportunity to attend a semester at Umeå University (Umeå, Sweden).

After graduating in 2017, she started the Master's program Bio-Pharmaceutical Sciences at Leiden University (Leiden, the Netherlands). As part of her Master's, she performed a nine-month internship at the division of Medicinal Chemistry (formerly known as Drug Discovery and Safety) under supervision of dr. Anna Vlachodimou and prof.dr. Laura H. Heitman. This project focused on the characterization of structure-affinity and structure-kinetic relationships of inhibitors for the equilibrative nucleoside transporter 1 (ENT1), which resulted in co-authorship on a publication. A second internship was performed at the Central Laboratory Animal Facility/Department of Anatomy and Embryology at Leiden University Medical Center (Leiden, the Netherlands) under the supervision of prof. dr. Daniela Salvatori where she performed a comparative analysis of stem-cell derived xenografts and human germ cell tumors. During the second year of her Master's Jara also joined the Leiden Leadership Program, an extracurricular honours program at Leiden University, for which she performed a consultancy project at insurance company Zorg en Zekerheid (Leiden, the Netherlands).

In 2019 she started as a PhD candidate at the division of Medicinal Chemistry of the LACDR under supervision of prof. dr. Laura H. Heitman and prof. dr. Mario van der Stelt. Her project focused on the molecular pharmacological characterization of the cannabinoid CB<sub>2</sub> receptor by applying novel drug discovery concepts. This project was funded by the Dutch Research Council (NWO Vidi #16573) and as such she frequently shared her research findings with experts in the field as part of the User Committee. Her PhD project was highly collaborative in nature, while she also took part in multiple external collaborations, reflected by the publications listed in this thesis. Moreover, she presented her work at national and international conferences. In 2022 she was awarded the EUFEPS Women in Pharmaceutical Sciences Award at the FIGON Dutch Medicines Days, as well as the predoctoral presentation award at the International Cannabinoid Research Society Meeting for her presentation 'Molecular basis for selective activation and target engagement of cannabinoid CB<sub>2</sub> receptor agonists'. In 2023 she visited the Pharma Research and Early Development site of F. Hoffmann-La Roche (Basel, Switzerland) as guest scientist for two weeks to get acquainted with preclinical drug research in the pharmaceutical industry.

Jara is currently working as program manager at ZonMw in Den Haag.



# Acknowledgements

I am grateful to have been surrounded by inspiring scientists and wonderful people these past years without whom my PhD and the work presented in this thesis would not have been realized. Hence, *it's about time* to thank all the remarkable people that have helped me through this journey.

First of all, I would like to express my gratitude to my promotors Laura and Mario for their trust, guidance and support during every stage of my PhD. Laura, your extensive pharmacological knowledge, dedication and constructive criticism have helped me become a better scientist. Mario, your knowledge of the cannabinoid field has challenged me to put results into perspective and focus on the bigger picture.

My PhD projects relied greatly on collaborations with various academic and industrial partners. I would like to convey my thanks to Xiaoting Li, Tian Hua (iHuman Institute, ShanghaiTech University), Pal Pacher (NIH), Anthe Janssen (Leiden Institute of Chemistry), Alessia Ligresti (National Research Council of Italy), Wolfgang Guba, Matthias Wittwer (Roche), Isabelle Geron (Revvity) and Sam Hoare (Pharmmechanics) for their significant theoretical, practical and analytical input. Your contributions have been key for the successful completion of my PhD. I wish to extend my appreciation to Ad IJzerman (LACDR), Herman van Vlijmen (Johnson & Johnson), Arne Rufer, Uwe Grether (Roche) and Rob Hermans (NWO), for their endless advice and support during all our Vidi meetings. I would like to give special credit to Uwe for initiating and inviting me to join many collaborations and welcoming me into his home whilst visiting Roche.

I am grateful to all my students, Jeremy, Sanjay, Silke, Ikram, Barry, Mea, Lynn, Jenny and Yasmine, for their enthusiasm and contributions to various projects in this thesis. Their help was invaluable to complete the projects and they have taught me to become a better supervisor.

Special thanks to all my colleagues from the division with whom I shared many scientific discussions, coffee breaks, lab outings, parties and more fun times. It was great being part of this group. In particular I want to thank Cas, Rongfang and Jaco for their excellent support in the lab. Lisa and Xuesong, thank you for your great scientific insights, but more importantly being there to just talk and vent about failed experiments and so much more. Inge, thank you for joining me to all the classes at the USC to clear our minds and just let go of the stress (for a bit). I have been lucky to have started this PhD journey alongside two more amazing female scientists. Majlen and Marina, thank you for the support that I received during the ups and downs of this PhD by means of dinner evenings, many glasses of wine or cocktails and relaxing spa trips.

## Acknowledgements

Thank you to all my friends for their fun distractions, support and down-to-earth perspective that have kept me going these years. Ilse, I am very grateful to have you by my side during my defense. Also lots of thanks to my family for their unconditional love and continuous support.

Lastly and most importantly, Sebas (or dr. Dekkers), you have been my favorite discovery during my PhD. You celebrated my achievements, supported me through the low points, and helped me put things into perspective. Thank you!







